COMPANY

SHY Therapeutics

HQ: Valhalla, NY source · shytherapeutics.com ↗

Keywords: small molecule oncology solid tumors cancer hematology Triple Negative Breast Cancer HR+ Breast Cancer Colon Cancer Gastric Cancer Hepatecellular Carcinoma NSCLC (Advanced Non-small Cell Lung Cancer) Mesothelioma Pancreatic Carcinoma Metastatic Hormone Refractory Prostate Cancer Soft Tissue Sarcomas SHY-ONC6

Location: Valhalla, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Funding and NIH signals

NIH award NIH awarded $287K (SBIR Phase I 5R43AI186577-02, continuation, notice Sep 10, 2026). NIH RePORTER 5R43AI186577-02 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · NIH RePORTER 5R43AI186577-02
  Organization: SHY THERAPEUTICS, LLC; City/State: HARRISON, NY; Project number: 5R43AI186577-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 286724; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel Class of Antifungal Therapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 24, 2026 Trial start Phase 1: A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors source ↗

Upcoming milestones

May 15, 2027 (ESTIMATED) · Phase 1 · A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors · NCT07705334

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07705334	A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Jun 24, 2026	May 15, 2027 (estimated)